RESEARCH ARTICLE

Cardiovascular Risk Factors and Ethnicity Are Independent Factors Associated with Lower Urinary Tract Symptoms

Jasmine Lim1*, Nirmala Bhoo-Pathy2,3*, Selvalingam Sothilingam1*, Rohan Malek4, Murali Sundram5, Guan Hee Tan6, Badrulhisham Bahadzor6, Teng Aik Ong1, Keng Lim Ng1,7, Azad Hassan Abdul Razack1*

1 Department of Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia, 2 Julius Center University of Malaya, Department of Social and Preventive Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia, 3 Primary Care, University Medical Center Utrecht, 3508GA, Utrecht, Netherlands, 4 Department of Urology, Selayang Hospital, Selangor, Malaysia, 5 Department of Urology, Kuala Lumpur Hospital, Kuala Lumpur, Malaysia, 6 Department of Surgery, University Kebangsaan Malaysia Medical Center, Kuala Lumpur, Malaysia, 7 Centre for Kidney Disease Research, School of Medicine, University of Queensland, Translational Research Institute, Brisbane, Australia

* These authors contributed equally to this work.

Abstract

Objectives

To determine the lower urinary tract symptoms (LUTS) profile and factors affecting its degree of severity including cardiovascular risk profile, age, ethnicity, education level and prostate volume in a multiethnic Asian setting.

Materials and Methods

We conducted a cross-sectional study of 1021 men aged 40–79 years with no clinical evidence of prostate cancer, prostate surgery or 5α-reductase inhibitor treatment of known prostate conditions. The severity of LUTS was assessed using the International Prostate Symptom Score (IPSS). Potential factors associated with LUTS including age, ethnicity, education, history of hypertension, diabetes and hypercholesterolemia, height, weight, and prostate volume were evaluated using univariable and multivariable analyses.

Results

There were 506 (50%) men found to have moderate-to-severe LUTS attaining an IPSS above 7. Overall, nocturia (45.5%) was the most frequently reported symptom. Multivariable analysis showed that age, ethnicity, prostate volume and history of hypertension and hypercholesterolemia were independent factors associated with severity of LUTS (p < 0.05). Considering individual lower urinary tract symptoms, we found a strong association of storage symptom with history of hypertension and hypercholesterolemia. Malay men were significantly bothered by post micturition symptom compared to their Chinese and Indian
counterparts. Stratified analyses of LUTS demonstrated a mutually exclusive cardiovascular risk factors profile defined by ethnicity.

**Conclusion**

Severity of LUTS varies between different ethnicities across all age groups. In addition to age and prostate volume, ethnicity and cardiovascular risk factors including hypertension and hypercholesterolemia may also need to be taken into account in managing men with LUTS.

**Introduction**

Lower urinary tract symptoms (LUTS) is subjective indicator of a disease or change in condition as perceived by the patient, partner or caregiver and may lead him / her to seek help from healthcare professionals. These symptoms are categorised into three groups including voiding symptoms (slow stream, splitting / spraying, intermittency, hesitancy, straining and terminal dribble), storage symptoms (increased daytime frequency, nocturia, urgency and urinary incontinence) and post micturition symptoms (feeling of incomplete emptying and post micturition dribble) [1]. The symptoms become increasingly common with age, impacting health-related quality of life [2].

The pathogenesis of LUTS remains to be fully elucidated. It has been hypothesised that LUTS may be attributed to endothelial dysfunction and pelvic atherosclerosis [3] that are closely linked to metabolic syndrome (MetS). Of note, MetS is a constellation of known cardiovascular risk factors including insulin resistance, obesity, atherogenic dyslipidemia and hypertension [4]. A high age-adjusted prevalence of MetS was observed in the U.S. population in which 22.9%–25.5% of adults being diagnosed with the syndrome from 1999 to 2010 based on the National Health and Nutrition Examination Survey [5]. Similar trend of MetS was recently reported in the multiethnic South East Asian population such as Malaysia (34.3%) [6] and Singapore (22.8%) [7] compared to other homogenous Asian populations in India (18.3%) [8], Hong Kong (9.6%) [9] and China (13.7%) [10].

There is emerging evidence suggesting associations between LUTS and MetS [11] or its components including obesity [12], hypertension and diabetes [13], although results have not been fairly consistent [14,15]. Therefore, it is of our interest to study the LUTS profiles amongst Asian men and improve the understanding of its potential link with MetS components. Malaysia is a high middle-income country in Southeast Asia with a multi-ethnic population encompassing mainly Malays, Chinese, Indians and indigenous races. We assessed the severity of LUTS across different age as well as ethnic groups and investigated the association of LUTS with age, ethnicity, education, anthropometric measurements (height, weight and prostate volume) and major comorbidities (diabetes, hypertension and hypercholesterolemia).

**Materials and Methods**

**Study subjects**

The current cross-sectional study was designed to recruit men above 40 years of age attending the prostate awareness campaign held in the Klang Valley, Malaysia in July 2011. There were eight participating hospitals in which five of them serve as tertiary referral centers for urology...
services in the region. Detailed methods of subject recruitment and data collection have been previously described [16].

A total of 1021 men were enrolled into the study. Clinical and demographic data such as age, ethnicity, education, height, weight and history of major comorbidities including diabetes, hypertension and hypercholesterolemia was ascertained using a structured questionnaire requiring input via face to face interviews, as well as medical examinations. LUTS were assessed using the validated IPSS (International Prostate Symptom Score) 7-item index [17]. All men underwent transrectal ultrasonography (TRUS) to determine the prostate volume. For assessment of voiding function, uroflowmetry was done to measure the maximum flow rate (Qmax) based on a minimum voided volume of 150 ml.

Each participant completed the interviews particularly the IPSS questionnaire and had no history of prostate cancer, previous history of prostate surgery or 5α-reductase inhibitor treatment of known prostate conditions. The baseline serum prostate specific antigen (PSA) level was measured in all subjects using total PSA assays described in [16]. Those of PSA > 4 ng/ml who refused for TRUS-guided prostate biopsy or confirmed with prostate cancer were excluded from the study. Overall, the serum PSA values ranged between 0.09–16.47 ng/ml.

All participants provided written informed consent. Ethical approval of this study was obtained from the medical research and ethics committee at the Ministry of Health Malaysia (code: NMRR-11-314-9262).

Data analysis

We first determined the severity of LUTS according to IPSS [17] by age groups (40–49, 50–59, 60–69 and 70–79 years) as well as ethnicity (Malay, Chinese and Indian). Lower urinary tract symptoms were further characterised into three groups; storage (frequency, nocturia & urgency), voiding (slow stream, intermittency & straining) and post micturition (incomplete emptying) symptoms. The ethnic heterogeneity of Qmax was examined using Kruskal-Wallis test.

Based on the severity of LUTS, participants were grouped into two categories using IPSS score > 7 as a cut-off point. Factors associated with LUTS including age, ethnicity, education, history of major comorbidities (diabetes, hypertension and hypercholesterolemia) and anthropometric variables (height, weight and prostate volume) were compared between two groups. We used univariable and multivariable logistic regression to study the associations of these variables with the severity of LUTS. The multivariable model was then used to explore potential clinical and demographic variables associated with storage, voiding or post micturition symptoms. In this analysis, the voiding and storage symptoms were dichotomised using a cut-off score of 3 whilst post micturition symptoms was defined with incomplete emptying score > 1.

In order to assess whether the association between ethnicity and severity of LUTS was modified by major comorbidities (diabetes, hypertension and hypercholesterolemia), likelihood ratio tests were applied between nested models with and without multiplicative interaction terms. The missing data in most of the variables was less than 0.5% except education level and prostate volume with around 6% and 25% respectively. This was expected owing to the more sensitive nature of socioeconomic status and invasive approach of measuring prostate volume using transrectal ultrasonography (TRUS). All statistical analysis was performed using SPSS for Windows version 21.0 (SPSS Inc., Chicago, Illinois, USA). Two-tailed P value < 0.05 was termed as statistically significant.
Results

There were 1021 men participated in the study and the median age was 59 years, ranging from 40 to 79 years. Most of the participants were Chinese (509; 49.9%), followed by Malays (367; 35.9%) and Indians (145; 14.2%). In term of major comorbidities, the proportions of subjects with history of hypercholesterolemia, diabetes and hypertension were 18.3%, 24.5% and 38.6% respectively.

In this study, 95% of subjects reported some degree of LUTS, of whom approximately half of the subjects reported moderate-to-severe LUTS (IPSS > 7), with a higher prevalence in men aged 70–79 years than those of 50–59 years (64% versus 43%) (Table 1). Differences in LUTS reporting were observed across various ethnicities in which Malay men (55%) were more likely to have moderate-to-severe LUTS symptoms compared to Chinese (48%) and Indians (42%). Interestingly, the median maximum flow rate (Qmax) of Malay, Chinese and Indian was 13.1 ml/s, 13.9 ml/s and 13.6 ml/s respectively ($p = 0.158$; Kruskal Wallis test), indicating that

| Table 1. The LUTS scores by age group and ethnicity. |
|-----------------------------------------------|
| **Age group (years)** | **Ethnicity** | **Malay** | **Chinese** | **Indian** | **Total** |
|-----------------------|--------------|-----------|-------------|------------|----------|
| IPSS                  |              |           |             |            |          |
| None                  | (0)          | 22        | 19          | 12         | 53       |
| Mild                  | (0–7)        | 144       | 246         | 72         | 462      |
| Moderate              | (8–19)       | 152       | 192         | 46         | 390      |
| Severe                | (20–35)      | 49        | 52          | 15         | 116      |
| Total                 |              | 72        | 477         | 382        | 90       | 1021     |
| Storage symptoms      |              |           |             |            |          |
| Frequency^             |              | 32        | 188         | 150        | 40       | 155      | 201      | 54       | 410     |
| Urgency^              |              | 19        | 107         | 113        | 37       | 109      | 122      | 45       | 276     |
| Nocturia†             |              | 27        | 181         | 197        | 60       | 170      | 231      | 64       | 465     |
| Voiding symptoms      |              |           |             |            |          |
| Intermittency^         |              | 24        | 140         | 131        | 40       | 140      | 160      | 35       | 335     |
| Weak stream^          |              | 29        | 161         | 152        | 45       | 152      | 189      | 46       | 387     |
| Straining^            |              | 15        | 87          | 78         | 23       | 75       | 103      | 25       | 203     |
| Postmicturition symptoms |              | 31        | 179         | 157        | 43       | 182      | 177      | 51       | 410     |

^ Subjects reporting the respective conditions with more than 1 time in 5 (score > 1) were recorded as having the symptoms.

† Nocturia was defined as having more than one episode per night.

doi:10.1371/journal.pone.0130820.t001
there is no association between ethnicity and Qmax. In addition, majority of individual lower urinary tract symptom became more prevalent with increasing age. Nocturia was the symptom (45.5%) most frequently found amongst all participants (Table 1).

Comparing LUTS in three clusters of urinary symptoms (Fig 1), storage scores were documented in approximately half of the individuals (489; 48%) and amongst these, 206 (42%) were bothered with both voiding and post micturition symptoms. Overall, 256 (25%) men had storage, voiding or post micturition symptoms only whilst combinations of these symptoms were observed in 413 (40%) subjects. For post micturition symptoms alone, nearly half of the Malay men (~ 53%) presented with the symptoms characterised by incomplete emptying (Fig 1). Chinese (44%) and Malays (43%) were more likely to have all three symptoms compared to their Indian counterparts (13%) (Fig 1).

Age, ethnicity, education, history of hypertension, diabetes and hypercholesterolemia as well as prostate volume were found to be significantly associated with moderate-to-severe LUTS (Table 2). For instance, participants with history of hypertension or hypercholesterolemia were 1.6-fold more likely than those without these medical conditions to have moderate-to-severe LUTS ($p < 0.01$). With every 1 year increase in age, there was a 1% rise in the probability of reporting moderate-to-severe LUTS ($p = 0.000$). We did not observe any significant associations between LUTS and height or weight. In the multivariable analysis, age, ethnicity, history of hypertension and hypercholesterolemia as well as prostate volume remained significantly and independently associated with moderate-to-severe LUTS (Table 3).

We then stratified the multivariable analysis according to ethnicity. Intriguingly, a mutually exclusive association pattern was observed between severity of LUTS and cardiovascular risk factors. For Indian, history of diabetes (adjusted OR 2.69, 95% CI 1.17–6.19) and hypercholesterolemia (adjusted OR 3.24, 95% CI 1.11–9.46) were strongly associated with moderate-to-severe LUTS whilst hypertension (adjusted OR 1.70, 95% CI 1.13–2.56) was found significantly related with severity of LUTS in Chinese only. Conversely, there were no association between cardiovascular risk profiles and LUTS in Malay. Collectively, cardiovascular risk factors did not seem to
modify the association between ethnicity and LUTS: history of diabetes ($p_{\text{interaction}} = 0.312$), hypertension ($p_{\text{interaction}} = 0.194$) and hypercholesterolemia ($p_{\text{interaction}} = 0.349$).

The multivariable model was further tested in three categories of LUTS consisting of storage, voiding and post micturition symptoms as summarised in Table 4. Malay ethnicity and history of hypertension were associated with post micturition symptoms. Age and components of cardiovascular risk factors including history of hypercholesterolemia as well as hypertension were independent factors of increased storage symptoms. For voiding symptoms, subjects with a prostate volume $\leq 30$ ml was 1.4-fold more likely than those of a lower prostate volume to present with a voiding score $> 3$ ($p = 0.043$), in addition to age. Both post micturition and

### Table 2. Comparison of factors associated with LUTS.

| Factors                  | Mild LUTS (IPSS $\leq 7$) | Moderate to severe LUTS (IPSS $> 7$) | OR  | 95% CI   | P     |
|--------------------------|---------------------------|-------------------------------------|-----|----------|-------|
| Age                      |                           |                                     |     |          |       |
| Median                   | 515                       | 506                                 | 1.04| 1.02–1.05| 0.000 |
| Ethnicity                |                           |                                     |     |          |       |
| Malay                    | 166                       | 201                                 | 1.00|          |       |
| Chinese                  | 265                       | 244                                 | 0.76| 0.58–1.00| 0.046 |
| Indian                   | 84                        | 61                                  | 0.60| 0.41–0.89| 0.10  |
| Education                |                           |                                     |     |          |       |
| Primary                  | 65                        | 89                                  | 1.00|          |       |
| Secondary                | 253                       | 227                                 | 0.66| 0.45–0.95| 0.024 |
| Tertiary                 | 166                       | 155                                 | 0.88| 0.46–1.01| 0.053 |
| *unknown                 | 31                        | 35                                  |     |          |       |
| Diabetes                 |                           |                                     |     |          |       |
| No                       | 405                       | 366                                 | 1.00|          |       |
| Yes                      | 110                       | 140                                 | 1.41| 1.06–1.88| 0.019 |
| Hypertension             |                           |                                     |     |          |       |
| No                       | 344                       | 283                                 | 1.00|          |       |
| Yes                      | 171                       | 223                                 | 1.59| 1.23–2.04| 0.000 |
| Hypercholesterolemia     |                           |                                     |     |          |       |
| No                       | 437                       | 397                                 | 1.00|          |       |
| Yes                      | 78                        | 109                                 | 1.54| 1.12–2.12| 0.009 |
| Height (m)               |                           |                                     |     |          |       |
| Median                   | 514                       | 503                                 | 0.99| 0.97–1.00| 0.137 |
| *unknown                 | 1                         | 3                                  |     |          |       |
| Weight (kg)              |                           |                                     |     |          |       |
| Median                   | 514                       | 503                                 | 1.00| 0.99–1.01| 0.953 |
| *unknown                 | 1                         | 3                                  |     |          |       |
| Prostate volume (ml)     |                           |                                     |     |          |       |
| $< 30$                   | 264                       | 229                                 | 1.00|          |       |
| $\geq 30$                | 115                       | 156                                 | 1.56| 1.16–2.11| 0.003 |
| *unknown                 | 136                       | 121                                |     |          |       |

Abbreviations: CI, confidence interval; IPSS, international prostate symptom score; LUTS, lower urinary tract voiding symptoms; OR, odds ratio.

doi:10.1371/journal.pone.0130820.t002
voiding symptoms were ~ 60% more likely to be found in men with lower education than those of tertiary education level.

### Discussion

Findings from this study provide an insight into the severity of LUTS in a large cohort of multi-ethnic Asian men. We demonstrated that there were significant ethnic variations in the prevalence of LUTS particularly in post micturition symptoms. Major elements of metabolic syndrome especially hypercholesterolemia and hypertension were significantly associated with LUTS.

LUTS are often attributed to the benign prostatic hyperplasia (prostate), detrusor overactivity-overactive bladder syndrome (bladder) or nocturnal polyuria (kidney) [18]. The population-based Olmsted County cohort study convincingly demonstrated an increase in LUTS over time [19]. Here, we revealed that age was significantly associated with moderate-to-severe LUTS. The age-dependent LUTS trend was consistently observed in previous multiethnic Asian population-based cross-sectional studies [20–22]. It is worth noting that the prevalence of the current study (49.6%, Table 1) is much higher than those previously reported ranged 6–29% [20–22], owing to different population sampling methods. Comparing to the randomised / multistage sampling technique adopted in previous reports [20–22], the nature of

| Factors          | Regression coefficient*  | OR    | 95% CI        | P       |
|------------------|--------------------------|-------|---------------|---------|
| **Age (year)†**  | 0.029                    | 1.03  | 1.01–1.05     | 0.002   |
| **Ethnicity**    |                          |       |               |         |
| Malay            | Baseline                 |       |               |         |
| Chinese          | -0.364                   | 0.70  | 0.52–0.93     | 0.015   |
| Indian           | -0.578                   | 0.56  | 0.37–0.84     | 0.005   |
| **Education**    |                          |       |               |         |
| Primary          | Baseline                 |       |               |         |
| Secondary        | -0.333                   | 0.72  | 0.49–1.05     | 0.089   |
| Tertiary         | -0.259                   | 0.77  | 0.51–1.16     | 0.213   |
| **Diabetes**     |                          |       |               |         |
| No               | Baseline                 |       |               |         |
| Yes              | 0.191                    | 1.21  | 0.88–1.66     | 0.240   |
| **Hypertension** |                          |       |               |         |
| No               | Baseline                 |       |               |         |
| Yes              | 0.304                    | 1.36  | 1.02–1.80     | 0.035   |
| **Hypercholesterolemia** |          |       |               |         |
| No               | Baseline                 |       |               |         |
| Yes              | 0.340                    | 1.41  | 1.00–1.97     | 0.049   |
| **Height (m)†**  | -0.005                   | 1.00  | 0.98–1.01     | 0.552   |
| **Weight (kg)†** | -0.004                   | 1.00  | 0.99–1.01     | 0.492   |
| **Prostate volume** |                      |       |               |         |
| < 30             | Baseline                 |       |               |         |
| ≥ 30             | 0.374                    | 1.45  | 1.06–1.99     | 0.019   |

*Multivariate model includes age, ethnicity, education level, history of diabetes, hypertension & hypercholesterolemia as well as prostate volume.
† Age (year), height (m) and weight (kg) considered as continuous variable within the multivariate model.

Abbreviations: CI, confidence interval; OR, odds ratio.

doi:10.1371/journal.pone.0130820.t003
current study design might hamper the sample by a selection bias although our aim was not to calculate prevalence rates.

To our knowledge, this is the first study which found ethnicity as an independent factor associated with LUTS particularly for post micturition symptom. Our results identified that Malay men were significantly more bothered with LUTS related to incomplete emptying and post micturition dribble than their Chinese and Indian counterparts. This could be attributed to the religious practice of most Malay as Muslims. It is part of their rituals to perform washing (wudhu) and be clean prior to performing the daily prayers. Therefore, post micturition symptoms have a greater impact on Malay (Muslim) men compared to other non-Muslim ethnicities. It is noteworthy that potential dietary and genetic factors which might explain fundamental differences in the presentation of urinary symptoms across various ethnicities remain under investigations. In addition, further analysis showed that there was no significant difference of median Qmax across different ethnicities suggesting that management of LUTS patients should be personalised based on the severity of storage, voiding and post micturition symptoms. This is because current treatment of LUTS with alpha-blocker monotherapy may improve one’s Qmax and benefits patients with storage or voiding symptoms only.

Our finding showed that a high prostate volume (e.g. ≥30 ml) was significantly associated with LUTS particularly in voiding symptoms, indicating that LUTS patients affected

Table 4. Multivariate analysis of factors associated with post micturition, voiding and storage symptoms.

| Factors               | Post micturition score > 1 OR (95% CI); P value | Voiding score > 3 OR (95% CI); P value | Storage score > 3 OR (95% CI); P value |
|-----------------------|-------------------------------------------------|----------------------------------------|----------------------------------------|
| Age (year)†           | 1.01 (0.99–1.03); 0.318                         | 1.02 (1.01–1.04); 0.015                | 1.04 (1.02–1.05); 0.000                |
| Ethnicity             |                                                 |                                        |                                        |
| Malay                 | 1.00                                            | 1.00                                   | 1.00                                   |
| Chinese               | 0.49 (0.36–0.66); 0.000                         | 0.89 (0.66–1.20); 0.440                | 0.85 (0.64–1.14); 0.289                |
| Indian                | 0.53 (0.35–0.80); 0.003                         | 0.72 (0.47–1.10); 0.126                | 0.74 (0.49–1.11); 0.141                |
| Education             |                                                 |                                        |                                        |
| Primary               | 1.00                                            | 1.00                                   | 1.00                                   |
| Secondary             | 0.62 (0.43–0.91); 0.016                         | 0.70 (0.48–1.03); 0.071                | 0.83 (0.57–1.23); 0.345                |
| Tertiary              | 0.57 (0.38–0.86); 0.008                         | 0.62 (0.41–0.93); 0.021                | 0.86 (0.57–1.29); 0.471                |
| Diabetes              |                                                 |                                        |                                        |
| No                    | 1.00                                            | 1.00                                   | 1.00                                   |
| Yes                   | 1.16 (0.84–1.59); 0.374                         | 1.26 (0.92–1.74); 0.157                | 1.02 (0.74–1.40); 0.895                |
| Hypertension          |                                                 |                                        |                                        |
| No                    | 1.00                                            | 1.00                                   | 1.00                                   |
| Yes                   | 1.36 (1.02–1.81); 0.038                         | 1.00 (0.75–1.33); 0.981                | 1.51 (1.14–2.00); 0.004                |
| Hypercholesterolemia  |                                                 |                                        |                                        |
| No                    | 1.00                                            | 1.00                                   | 1.00                                   |
| Yes                   | 0.90 (0.64–1.27); 0.559                         | 1.37 (0.98–1.91); 0.071                | 1.55 (1.11–2.17); 0.011                |
| Height (m)†           | 0.99 (0.97–1.01); 0.292                         | 1.00 (0.98–1.01); 0.584                | 1.00 (0.98–1.02); 0.969                |
| Weight (kg)†          | 0.99 (0.98–1.00); 0.106                         | 1.00 (0.98–1.01); 0.455                | 1.00 (0.99–1.01); 0.791                |
| Prostate volume (ml)  |                                                 |                                        |                                        |
| < 30                  | 1.00                                            | 1.00                                   | 1.00                                   |
| ≥ 30                  | 1.01 (0.74–1.39); 0.947                         | 1.39 (1.01–1.90); 0.042                | 1.30 (0.95–1.78); 0.096                |

† Age (year), height (m) and weight (kg) considered as continuous variables within the multivariate model.

Abbreviations: CI, confidence interval; OR, odds ratio.

doi:10.1371/journal.pone.0130820.t004
predominantly with voiding symptoms are likely to have a bigger prostate compared to those bothered by other urinary symptoms. Roehrborn et al [23] analysed long term symptoms changes in relation to prostate volume amongst the placebo-treated men with moderate-to-severe LUTS for 4 years in the Proscar Long Term Efficacy and Safety Study and determined that high baseline enlarged prostate volume predicted deterioration of LUTS over time. This is further supported by results from the Medical Therapy of Prostatic Symptoms trial placebo group showing baseline prostate volume correlated significantly with the American Urological Association symptom index score [24].

Increased post micturition or voiding score was linked with education level. This is consistent with the epidemiological dogma in which a low education level or socioeconomic status is linked to more disease of any kind. The discrepancy also suggests that men are more aware and could tolerate better with storage symptoms compared to post micturition and voiding symptoms, regardless of the education level.

Furthermore, we observed an independent association between LUTS and cardiovascular risk factors including history of hypertension and hypercholesterolemia, especially in storage and post micturition symptoms. The association between LUTS and cardiovascular risk factors has been previously documented [13,20,25]; nevertheless, several of our findings are novel particularly those associated with specific urinary symptoms groups. For instance, metabolic syndrome [11] or a low level of high density lipoprotein [26] was previously associated with voiding symptoms only. Results from the present study add to the growing literature that underlying medical illness (i.e. hypertension and hypercholesterolemia) may also impact in storage and post micturition symptoms. Previous studies proposed that pelvic atherosclerosis specifically ischemia and endothelial dysfunction, which contributed to decreased nitric oxide (NO) bioavailability, were potential entities linking between MetS and LUTS. Notably, NO is crucial in maintaining vascular health by inhibiting adhesion of platelets and leukocytes to the vascular wall as well as decreasing proliferation of vascular smooth muscle which may result in initiation of atherosclerosis [27]. Under the low NO levels in MetS, excessive RHO-kinase (ROK) activation can result in greater tonic prostatic smooth muscle contraction contributing to LUTS [28]. In addition, pre-clinical data using hyperlipidemic rats model demonstrated that prostatic enlargement and bladder overactivity were consistently observed in rats with high serum cholesterol and low density lipoprotein [29], indicating the role of cardiovascular risk factors in promoting LUTS.

Our study findings provide a new understanding of LUTS profiles according to storage, voiding and post micturition symptoms within a multiethnic Asian population. This is also the first documented evidence of ethnicity as an independent factor associated with moderate-to-severe LUTS particularly in post micturition symptoms. The study highlighted the significant association between LUTS and cardiovascular risk profile including history of hypertension and hypercholesterolemia, in addition to age and prostate volume. Increased odds of hypercholesterolemia and hypertension were described with storage scores > 3. With the recognition of association between cardiovascular risk factors and urologic symptoms, we would like to recommend that clinicians should consider screening patients presenting with urologic symptoms for cardiovascular risk factors. Similarly, the LUTS-IPSS index should be assessed whilst planning treatment for patients with hypertension and hypercholesterolemia. Another important clinical implication of this study is that ethnicity and severity of different groups of urological symptoms may also need to be taken into account in addressing the management of LUTS, in addition to age and prostate volume.
Acknowledgments

We thank the National Clinical Research Center (CRC), all associates in the Urology Unit and diagnostic laboratories across all participating hospitals for the work on organising and running the PSA tests during the prostate awareness campaign. We are grateful to Prema Muni-nathan for assistance with the ethical approval application. This study has won the best oral presentation in the 23rd Malaysian Urological Conference.

Author Contributions

Conceived and designed the experiments: SS RM MS GHT BB TAO KLN AHAR. Performed the experiments: JL NBP SS RM MS GHT BB TAO KLN AHAR. Analyzed the data: JL NBP SS AHAR. Contributed reagents/materials/analysis tools: JL NBP SS RM MS GHT BB TAO KLN AHAR. Wrote the paper: JL NBP SS AHAR.

References

1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. (2002) The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21: 167–178. PMID: 11857671
2. Kupelian V, Wei JT, O'Leary MP, Kusek JW, Litman HJ, Link CL, et al. (2006) Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) Survey. Arch Intern Med 166: 2381–2387. PMID: 17130393
3. McVary K (2006) Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology. BJU Int 97 Suppl 2: 23–28; discussion 44–25. PMID: 16507050
4. Alberti KG, Zimmet P, Shaw J (2006) Metabolic syndrome—a new worldwide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 23: 469–480. PMID: 16681555
5. Beltran-Sanchez H, Harhay MO, Harhay MM, McElligott S (2013) Prevalence and trends of metabolic syndrome in the adult U.S. population, 1999–2010. J Am Coll Cardiol 62: 697–703. doi: 10.1016/j.jacc.2013.05.064 PMID: 23810877
6. Mohamud WN, Ismail AA, Sharifuddin A, Ismail IS, Musa KI, Kadir KA, et al. (2011) Prevalence of metabolic syndrome and its risk factors in adult Malaysians: results of a nationwide survey. Diabetes Res Clin Pract 91: 239–245. doi: 10.1016/j.diabres.2010.11.025 PMID: 21146882
7. Lee J, Heng D, Ma S, Chew SK, Hughes K, Tai ES (2008) The metabolic syndrome and mortality: the Singapore Cardiovascular Cohort Study. Clin Endocrinol (Oxf) 69: 225–230. doi: 10.1111/j.1365-2265.2008.03174.x PMID: 18208579
8. Deepa M, Farooq S, Datta M, Deepa R, Mohan V (2007) Prevalence of metabolic syndrome using WHO, ATPIII and IDF definitions in Asian Indians: the Chennai Urban Rural Epidemiology Study (CURES-34). Diabetes Metab Res Rev 23: 127–134. PMID: 16752431
9. Ko GT, Cockram CS, Chow CC, Yeung VT, Chan WB, So WY, et al. (2006) Metabolic syndrome by the international diabetes federation definition in Hong Kong Chinese. Diabetes Res Clin Pract 73: 58–64. PMID: 16406127
10. Gu D, Reynolds K, Wu X, Chen J, Duan X, Reynolds RF, et al. (2005) Prevalence of the metabolic syndrome and overweight among adults in China. Lancet 365: 1398–1405. PMID: 15836888
11. Kupelian V, McVary KT, Kaplan SA, Hall SA, Link CL, Aiyer LP, et al. (2009) Association of lower urinary tract symptoms and the metabolic syndrome: results from the Boston Area Community Health Survey. J Urol 182: 616–624; discussion 624–615. doi: 10.1016/j.jpuro.2009.04.025 PMID: 19539955
12. Parsons JK, Messer K, White M, Barrett-Connor E, Bauer DC, Marshall LM (2011) Obesity increases and physical activity decreases lower urinary tract symptom risk in older men: the Osteoporotic Fractures in Men study. Eur Urol 60: 1173–1180. doi: 10.1016/j.eururo.2011.07.040 PMID: 21802828
13. Fitzgerald MP, Link CL, Litman HJ, Travison TG, McKinlay JB (2007) Beyond the lower urinary tract: the association of urologic and sexual symptoms with common illnesses. Eur Urol 52: 407–415. PMID: 17382498
14. Temml C, Obermayr R, Marszalek M, Rauchwold M, Madersbacher S, Ponholzer A (2009) Are lower urinary tract symptoms influenced by metabolic syndrome? Urology 73: 544–548. doi: 10.1016/j.urology.2008.10.027 PMID: 19118673
15. Zamuner M, Laranja WW, Alonso JC, Simoes FA, Rejowski RF, Reis LO (2014) Is metabolic syndrome truly a risk factor for male lower urinary tract symptoms or just an epiphenomenon? Adv Urol 2014: 203854. doi:10.1155/2014/203854 PMID: 24587797

16. Lim J, Bhoo-Pathy N, Sothilingam S, Malek R, Sundram M, Hisham Bahadzor B, et al. (2014) Ethnicity is an independent determinant of age-specific PSA level: findings from a multiethnic Asian setting. PLoS One 9: e104917. doi: 10.1371/journal.pone.0104917 PMID: 25115057

17. Barry MJ, Fowler FJ Jr., O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, et al. (1992) The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 148: 1549–1557; discussion 1564. PMID: 1279218

18. Chapple CR, Roehrborn CG (2006) A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 49: 651–658. PMID: 16530611

19. Jacobsen SJ, Girman CJ, Guess HA, Rhodes T, Oesterling JE, Lieber MM (1996) Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men. J Urol 155: 595–600. PMID: 8558668

20. Chong C, Fong L, Lai R, Koh YT, Lau WK, Hartman M, et al. (2012) The prevalence of lower urinary tract symptoms and treatment-seeking behaviour in males over 40 years in Singapore: a community-based study. Prostate Cancer Prostatic Dis 15: 273–277. doi: 10.1038/pca.2011.69 PMID: 22349985

21. Mariappan P, Chong WL (2006) Prevalence and correlations of lower urinary tract symptoms, erectile dysfunction and incontinence in men from a multiethnic Asian population: Results of a regional population-based survey and comparison with industrialized nations. BJU Int 98: 1264–1268. PMID: 17034498

22. Khoo EM, Tan HM, Low WY (2008) Erectile dysfunction and comorbidities in aging men: an urban cross-sectional study in Malaysia. J Sex Med 5: 2925–2934. doi: 10.1111/j.1743-6109.2008.00988.x PMID: 18761590

23. Roehrborn CG, Boyle P, Bergner D, Gray T, Gittelman M, Shown T, et al. (1999) Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group. Urology 54: 662–669. PMID: 10519025

24. Kaplan SA, Lee JY, Meehan AG, Kusek JW (2011) Long-term treatment with finasteride improves clinical progression of benign prostatic hyperplasia in men with an enlarged versus a smaller prostate: data from the MTOPS trial. J Urol 185: 1369–1373. doi: 10.1016/j.juro.2010.11.060 PMID: 21334655

25. Kok ET, Schouten BW, Bohnen AM, Groeneveld FP, Thomas S, Bosch JL (2009) Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study. J Urol 181: 710–716. doi: 10.1016/j.juro.2008.10.025 PMID: 19091352

26. Martin S, Lange K, Haren MT, Taylor AW, Wittert G (2014) Risk factors for progression or improvement of lower urinary tract symptoms in a prospective cohort of men. J Urol 191: 130–137. doi: 10.1016/j.juro.2013.06.018 PMID: 23770136

27. Creager MA, Luscher TF, Cosentino F, Beckman JA (2003) Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation 108: 1527–1532. PMID: 14504252

28. Rees RW, Foxwell NA, Ralph DJ, Kell PD, Moncada S, Celtek S (2003) Y-27632, a Rho-kinase inhibitor, inhibits proliferation and adrenergic contraction of prostatic smooth muscle cells. J Urol 170: 2517–2522. PMID: 14634463

29. Rahman NU, Phonsombat S, Bochinski D, Carrion RE, Nunes L, Lue TF (2007) An animal model to study lower urinary tract symptoms and erectile dysfunction: the hyperlipidaemic rat. BJU Int 100: 658–663. PMID: 17590178